Register for free to
view the full innovation profile.
Technology # 16-06 A technology for Enhanced Wound Healing Fibroblast Growth Factor (FGF) is a naturally occurring substance in the body that has many roles.
About
Technology # 16-06 A technology for Enhanced Wound Healing Fibroblast Growth Factor (FGF) is a naturally occurring substance in the body that has many roles. One of them is to help heal wounds, FGF causes the wound to grow new blood vessels and new nerves. Currently FGF is used commercially to help in the healing of wounds, however, the version of FGF now used for this purpose is quickly degraded by the presence near a wound of thrombin, which is a blood coagulant. A new type of engineered FGF has been invented that resists the degradation of thrombin, and has higher biological activity in the blood stream, thus leading to its being more effective in wound healing. The new version of FGF has been shown to have twice the wound healing property of natural FGF. The invention is available for licensing. For interested parties seeking further information, feel free to contact: Mark Allen Lanoue Technology Manager / Tech Ventures University of Arkansas (479) 575-7243 [email protected]
Key Benefits
Advantage(s): * Biologically extremely active * Thrombin Resistant * Thermo stable * Economically viable * Stable upon pro-longed storage * Heparin independent mitogenic activity
Applications
Application(s): This mutant R136E of the present invention can be used primarily for wound healing purposes. Because of its higher stability, we can develop FGF-I RI 36E coated surgical patches that can be applied on the wounds directly. As this mutant is thermo stable, major advantage will be the product can be stored and supplied at room temperature, Also the shelf life of the product would be drastically increased. Apart from this due to its resistance to thrombin, it can stay active for a long time in blood stream and can show maximal activity for a prolonged duration of time. By developing a proper delivery system, FGF-I R136E can be directed to the site of internal injury and look for the regeneration of the wounded tissue. A formulation consisting of FGF-l R136E and collagen binding protein and pituitary hormone can be very effective to treat Osteoporosis. Other The present invention has many advantages over the existing product in the market. The molecule FGF-I R136E is extremely stable and shows much higher bioactivity compared to the existing RI 36K. Also, this mutant has a higher thermal stability compared to the wild type and the RI 36K mutant. Further the mutant showed a reduced affinity for heparin which makes it more interesting and intriguing in terms of clinical point of view.